Skip to main content
  • Contact
  • Login
  • Our Company
    • Our Company
    • Mission
    • Leadership
  • Clinical Studies
    • Clinical Studies
    • ECLIPSE
    • GRECO-Breast Cancer
  • Solutions
    • Solutions
    • Treatment Selection
    • Residual Disease & Recurrence Monitoring
    • Early Detection
    • Biopharma Solutions
  • International
  • Investors
    • Investors
  • Media
    • Media
    • Press Releases
    • Resources and Media Assets
    • Contacts
  • Careers
    • Careers
    • Join Our Mission
    • Making Their Mark
    • Our Values
    • Benefits
    • Jobs
Guardant Health

Press Releases

Investors Menu
  • Home
    • Press Releases
    • Events & Presentations
      • Events
      • Presentations
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Financials
      • Quarterly Results
      • Annual Reports
      • SEC Filings
    • Corporate Governance
      • Governance Documents
      • Leadership
      • Board of Directors
      • Committee Composition
    • Resources
      • Investor FAQs
      • Investor Email Alerts
      • Investor Contacts
Normal
Press Release RSS Feed (opens in new window)
Press release year list 2021 2020 2019 2018 2017
February 24, 2021
Guardant Health Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Revenue Outlook for Full Year 2021
February 17, 2021
Guardant Health to Participate in Upcoming Investor Conferences
February 16, 2021
Guardant Health Launches Guardant Reveal™ Liquid Biopsy Test for Residual Disease and Recurrence Monitoring in Patients with Early-Stage Colorectal Cancer
February 4, 2021
Guardant Health to Report Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021
January 27, 2021
Head-to-Head Study Shows Guardant360 Liquid Biopsy Outperforms Tissue Biopsy for Comprehensive Genomic Profiling in Advanced Non-Small Cell Lung Cancer with Similar Outcomes
January 18, 2021
Guardant Health and Vall d’Hebron Institute of Oncology Announce Partnership to Establish First Guardant-Based Liquid Biopsy Testing Service in Europe
January 14, 2021
Guardant Health to Present Data at ASCO Gastrointestinal Cancers Symposium Showing Value of Liquid Biopsy to Advance Precision Oncology in Early to Late-Stage Colorectal Cancer

Quick Links

  • SEC Filings
  • Investor FAQs

IR Contact

Carrie Mendivil

415-937-5405
investors@guardanthealth.com

Investor Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Guardant Health Inc. to send you the requested Investor Email Alert updates.

* Required

*
*
Unsubscribe

Email Alert Sign Up Confirmation

REQUEST A MEETING WITH MANAGEMENT
  • Our Company
    • Mission
    • Leadership

    • International
  • Solutions
    • Treatment Selection
    • Recurrence Detection
    • Early Detection
  • Careers
    • Join Our Mission
    • Making Their Mark
    • Our Values
    • Benefits
    • Jobs
  • Investors
  • Guardant Health, Inc.

    505 Penobscot Dr.
    Redwood City, CA 94063

    Telephone: 855.698.8887
    Fax: 888.974.4258

    Contact us:
    clientservices@guardanthealth.com

    Media inquiries:
    press@guardanthealth.com

© Guardant Health

CLIA # 05D2070300 | CAP Accredited # 8765297 | Terms of Use | Privacy Policy | Notice of Privacy Practices
Powered By Q4 Inc. 5.51.0.5 (opens in new window)